Family Management Corp Makes New $1.77 Million Investment in Hologic, Inc. (NASDAQ:HOLX)

Family Management Corp purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 25,374 shares of the medical equipment provider's stock, valued at approximately $1,774,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of HOLX. Norges Bank acquired a new position in Hologic in the 4th quarter valued at about $133,414,000. Boston Partners increased its stake in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. Champlain Investment Partners LLC acquired a new stake in Hologic during the 4th quarter worth approximately $79,291,000. Northern Trust Corp boosted its stake in Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after purchasing an additional 668,086 shares during the period. Finally, Invesco Ltd. grew its holdings in Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after buying an additional 572,187 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Insiders Place Their Bets

In other news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.88% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on HOLX shares. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Evercore ISI lowered their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Raymond James reissued an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Finally, Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $78.58.

Hologic Stock Up 1.0 %

NASDAQ:HOLX traded up $0.56 during trading hours on Friday, hitting $56.74. 3,258,934 shares of the company traded hands, compared to its average volume of 2,092,764. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm's 50-day simple moving average is $59.43 and its 200-day simple moving average is $68.25. The company has a market cap of $12.73 billion, a PE ratio of 17.90, a PEG ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the business posted $1.03 earnings per share. Hologic's revenue was down 1.2% on a year-over-year basis. Equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.